CXCR4 and hepatocellular carcinoma: All in all, CXCR4 seems to be a valuable target in HCC, and with its agonist MozobilTM (AMD3100) already approved by the FDA [247], there is a solid possibility that its testing in HCC combined therapy will happen soon.